<DOC>
	<DOCNO>NCT00903721</DOCNO>
	<brief_summary>The investigation conduct define safety efficacy condition post-marketing use drug subject allergic rhinitis . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation ( Study P05876 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Patients treat Nasonex perennial seasonal allergic rhinitis . Patients infection effective antimicrobial drug systemic fungal infection [ symptom may exacerbate ] Patients history hypersensitivity ingredient drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>